Akorn exits vaccine distribution business Akorn.

Exiting the vaccine distribution business allows our sales force to focus on new product launches and on higher margin products. We expect a clean transition of the Td vaccine business and will continue steadily to support our existing client needs through our source chain.?.. Akorn exits vaccine distribution business Akorn, Inc. The prevailing supply agreement will end on March 14, 2010. The business previously announced its intent to exit the distribution of flu vaccines. Furthermore, the Td vaccine business produced excessive monetary burden on the business since its launch and is expected to contribute only marginally to operating profits in 2009 2009.Randomization was stratified according to trial middle and according to the randomization assignments in the overarching ARROW trial . The computer-generated, sequentially numbered randomization list was made by the trial statistician and was included within the secure data source at each trial center. Randomization was performed by clinicians telephoning the local trial center. Trial managers could access the next number on the list but not the whole list. Participants visited a doctor and underwent a complete bloodstream count, CD4 T-cell count, and liver-function and renal-function lab tests at randomization and every 12 weeks thereafter.